论文部分内容阅读
目的:探讨护肝片联合替诺福韦酯治疗慢性乙型肝炎疗效及对患者细胞炎性因子和血管内皮功能的影响。方法:选择东阳市人民医院于2017年1月至2018年12月收治的慢性乙型肝炎患者100例，按照随机数字表法分为观察组50例与对照组50例。对照组患者给予替诺福韦酯治疗，观察组在对照组基础上给予护肝片治疗。两组疗程均为48周。比较两组治疗疗效和乙肝病毒DNA(HBV-DNA)阴转情况，治疗前后肝功能、细胞炎性因子和血管内皮功能变化。结果:观察组总有效率(92.00%)高于对照组(72.00%)(χn 2＝6.775，n P<0.05)；观察组HBV-DNA阴转率(68.00%)高于对照组(50.00%)(χn 2＝4.105，n P<0.05)；观察组治疗后血清天冬氨酸氨基转移酶(51.28±7.29)U/L、总胆红素(16.69±3.18)μmol/L和丙氨酸氨基转移酶(48.93±7.87)U/L，均低于对照组的(81.32±14.25)U/L、(24.31±5.47)μmol/L和(94.34±18.37)U/L(n t＝13.271、8.516、16.067，均n P<0.05)；观察组治疗后血清白细胞介素2(178.38±19.98)ng/L，高于对照组的(131.07±13.42)ng/L，而白细胞介素4(38.19±6.19)ng/L和白细胞介素10(48.93±7.87)ng/L，低于对照组的(54.76±5.84)ng/L和(94.34±18.37)ng/L(n t＝13.899、13.768、16.067，均n P<0.05)；观察组治疗后血清血管内皮生长因子(101.32±8.78)ng/L、内皮素1(34.82±2.97)ng/L，均低于对照组的(127.90±15.46)ng/L和(38.98±3.41)ng/L(n t＝10.571、6.505，均n P<0.05)。n 结论:护肝片联合替诺福韦酯对慢性乙型肝炎患者疗效良好，可改善患者肝功能、减轻细胞炎性反应及改善患者血管内皮功能。“,”Objective:To investigate the therapeutic effect of Hugan tablet combined with tenofovir disoproxil on patients with chronic hepatitis B and its influence on the cellular inflammatory factors and vascular endothelial function.Methods:From January 2017 to December 2018, 100 patients with chronic hepatitis B admitted to Dongyang People's Hospital were randomly divided into observation group (50 cases) and control group (50 cases) according to the random digital table method.The control group was treated with tenofovir disoproxil, while the observation group was treated with Hugan tablet on the basis of the control group.The course of treatment in both two groups was 48 weeks.The therapeutic effect and HBV-DNA negative transformation of the two groups were compared, and the changes of liver function, cytokines and vascular endothelial function before and after treatment were compared.Results:The total effective rate of the observation group (92.00%) was higher than that of the control group (72.00%) (χn 2=6.775, n P<0.05). The negative rate of HBV-DNA in the observation group (68.00%) was higher than that in the control group (50.00%) (χn 2=4.105, n P<0.05). The serum AST[(51.28±7.29)U/L], TBIL[(16.69±3.18)μmol/L] and ALT[(48.93±7.87)U/L] in the observation group were lower than those in the control group [(81.32±14.25)U/L, (24.31±5.47)μmol/L and (94.34±18.37)U/L] (n t=13.271, 8.516 and 16.067, all n P<0.05). The serum IL-2 [(178.38±19.98)ng/L] in the observation group was higher than that in the control group [(131.07±13.42)ng/L], while the serum IL-4 [(38.19±6.19)ng/L] and IL-10 [(48.93±7.87)ng/L] in the observation group were lower than those in the control group [(54.76±5.84)ng/L and (94.34±18.37)ng/L] (n t=13.899, 13.768, 16.067, all n P<0.05). The serum VEGF[(101.32±8.78)ng/L] and ET-1[(34.82±2.97)ng/L] in the observation group were lower than those in the control group [(127.90±15.46)ng/L and (38.98±3.41)ng/L] (n t=10.571, 6.505, all n P<0.05).n Conclusion:Hugan tablet combined with tenofovir disoproxil has good therapeutic effect on patients with chronic hepatitis B, which can improve the liver function, reduce the inflammatory reaction of cells and improve the vascular endothelial function.